[FG] Kuhle Jens

Schindler, P. et al. (2024) ‘Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study’, Multiple Sclerosis and Related Disorders, 88. Available at: https://doi.org/10.1016/j.msard.2024.105729.

Zivadinov, R. et al. (2024) ‘Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA–MS case-controlled study’, Journal of Neurology, 271(8), pp. 4949–4962. Available at: https://doi.org/10.1007/s00415-024-12420-2.

Fischbach, F. et al. (2024) ‘CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis’, Med, 5(6), pp. 550–558.e2. Available at: https://doi.org/10.1016/j.medj.2024.03.002.

Maatta, L.L. et al. (2024) ‘Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark’, Diabetes Care, 47(6), pp. 986–994. Available at: https://doi.org/10.2337/dc23-2208.

Sharmin, S. et al. (2024) ‘Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries’, The Lancet Child and Adolescent Health, 8(5), pp. 348–357. Available at: https://doi.org/10.1016/S2352-4642(24)00047-6.

Spelman, T. et al. (2024) ‘Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase’, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 10(2). Available at: https://doi.org/10.1177/20552173241247182.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv [Preprint]. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.03.22.24304720.

Geis, T. et al. (2024) ‘Neurofilament Light Chain Concentration in Cerebrospinal Fluid in Children with Acute Nontraumatic Neurological Disorders’, Children, 11(3). Available at: https://doi.org/10.3390/children11030360.

Galbusera, Riccardo et al. (2024) ‘Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis’, Neurology, 102(3). Available at: https://doi.org/10.1212/wnl.0000000000207966.

Rusche, Thilo et al. (2024) ‘Anti-GABAA receptor encephalitis 14 months after allogeneic haematopoietic stem-cell transplant for acute myeloid leukaemia’, The Lancet, 403(10425), pp. 469–470. Available at: https://doi.org/10.1016/s0140-6736(23)02831-3.

Linnemann, Christoph et al. (2024) ‘NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study’, Journal of Neurology, Neurosurgery & Psychiatry, pp. jnnp–2023–332464. Available at: https://doi.org/10.1136/jnnp-2023-332464.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Pontillo, G. et al. (2024) ‘Disentangling neurodegeneration from ageing in multiple sclerosis: the brain-predicted disease duration gap’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.01.02.23300497.

Callegari, Ilaria et al. (2024) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’, Brain, 147, pp. 839–848. Available at: https://doi.org/10.1093/brain/awad424.

Chalkou, Konstantina et al. (2024) ‘Combining randomized and non-randomized data to predict heterogeneous effects of competing treatments’, Research Synthesis Methods, 15, pp. 641–656. Available at: https://doi.org/10.1002/jrsm.1717.

Freedman, Mark S. et al. (2024) ‘Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management’, eBioMedicine, 101. Available at: https://doi.org/10.1016/j.ebiom.2024.104970.

Galbusera, Riccardo et al. (2024) ‘Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis’, Neurology, 102, p. e207966. Available at: https://doi.org/10.1212/wnl.0000000000207966.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials. 11.09.2024, 25. Available at: https://doi.org/10.1186/s13063-024-08454-6.

Khalil, Michael et al. (2024) ‘Neurofilaments as biomarkers in neurological disorders — towards clinical application’, Nature Reviews Neurology, 20, pp. 269–287. Available at: https://doi.org/10.1038/s41582-024-00955-x.

Kuhle, J. (2024) ‘Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis’, Therapeutic Advances in Neurological Disorders, 17. Available at: https://doi.org/10.1177/17562864241239101.

Linnemann, Christoph et al. (2024) ‘NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study’, Journal of Neurology, Neurosurgery and Psychiatry, null. Available at: https://doi.org/10.1136/jnnp-2023-332464.

Montalban, Xavier et al. (2024) ‘Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study’, Multiple Sclerosis Journal, 30, pp. 558–570. Available at: https://doi.org/10.1177/13524585241234783.

Dekeyser, C. et al. (2024) ‘Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study’, Journal of Neurology, Neurosurgery and Psychiatry, pp. jnnp–2023–333307. Available at: https://doi.org/10.1136/jnnp-2023-333307.

Roos, I. et al. (2024) ‘Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis’, Multiple Sclerosis Journal [Preprint]. Available at: https://doi.org/10.1177/13524585241267211.

Signori, Alessio et al. (2024) ‘Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry’, Journal of Neurology, Neurosurgery and Psychiatry, null. Available at: https://doi.org/10.1136/jnnp-2023-332603.

Wang, Angela A. et al. (2024) ‘B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans’, Science Translational Medicine, 16. Available at: https://doi.org/10.1126/scitranslmed.adi0295.

Zuo, Michelle et al. (2024) ‘Erratum: Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation (JCI insight PII: e183445)’, JCI insight, 9. Available at: https://doi.org/10.1172/jci.insight.183445.

Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), p. 1317. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.

Leone, Maurizio A. et al. (2023) ‘Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis’, Cell Stem Cell, 30(12), pp. 1597–1609.e8. Available at: https://doi.org/10.1016/j.stem.2023.11.001.

Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis’, JAMA Neurology, 80(11), p. 1232. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.

Callegari, I. et al. (2023) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.09.29.560121.

Bar-Or, Amit et al. (2023) ‘Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials’, eBioMedicine, 93, p. 104662. Available at: https://doi.org/10.1016/j.ebiom.2023.104662.

Andreasson U et al. (2023) ‘Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood.’, Clinical chemistry and laboratory medicine, 61(7), pp. 1245–1254. Available at: https://doi.org/10.1515/cclm-2022-1181.

Cagol A. et al. (2023) ‘Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.’, Journal of neurology, 270(4), pp. 2139–2148. Available at: https://doi.org/10.1007/s00415-022-11535-8.

Margraf NG et al. (2023) ‘Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus.’, Journal of neurology, 270(4), pp. 2128–2138. Available at: https://doi.org/10.1007/s00415-022-11547-4.

Vermunt, L. et al. (2023) ‘Axonal damage and astrocytosis are biological correlates of grey matter network integrity loss: a cohort study in autosomal dominant Alzheimer disease’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.03.21.23287468.

Kuhle J et al. (2023) ‘Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial’, Multiple Sclerosis Journal, 29(3), pp. 385–394. Available at: https://doi.org/10.1177/13524585221144742.

Montalban X et al. (2023) ‘Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.’, Annals of clinical and translational neurology, 10(3), pp. 302–311. Available at: https://doi.org/10.1002/acn3.51732.

Tsagkas C et al. (2023) ‘Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis’, Multiple Sclerosis and Related Disorders, 71, p. 104545. Available at: https://doi.org/10.1016/j.msard.2023.104545.

Telser, J. et al. (2023) The role of serum brain injury biomarkers in individuals with a mild-to-moderate COVID infection and Long-COVID - results from the prospective population-based COVI-GAPP study. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.02.15.23285972.

Abu-Rumeileh S et al. (2023) ‘The multifaceted role of neurofilament light chain protein in non-primary neurological diseases.’, Brain : a journal of neurology, 146(2), pp. 421–437. Available at: https://doi.org/10.1093/brain/awac328.

Spelman T et al. (2023) ‘Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.’, Multiple sclerosis (Houndmills, Basingstoke, England), 29(2), pp. 221–235. Available at: https://doi.org/10.1177/13524585221137502.

Abdelhak, Ahmed, Kuhle, Jens and Green, Ari J. (2023) ‘Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain’, JAMA Neurology, 80, pp. 542–543. Available at: https://doi.org/10.1001/jamaneurol.2023.0394.

Bar-Or, Amit et al. (2023) ‘Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials’, eBioMedicine, 93. Available at: https://doi.org/10.1016/j.ebiom.2023.104662.

Bavato, Francesco et al. (2023) ‘A Longitudinal Investigation of Blood Neurofilament Light Chain Levels in Chronic Cocaine Users’, Molecular Neurobiology, 60, pp. 3935–3944. Available at: https://doi.org/10.1007/s12035-023-03327-6.

Butzkueven, Helmut et al. (2023) ‘The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis’, Current Medical Research and Opinion, 39, pp. 1367–1374. Available at: https://doi.org/10.1080/03007995.2023.2256220.

Callegari, Ilaria et al. (2023) ‘Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150040.

Cerdá-Fuertes, Nuria et al. (2023) ‘Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150312.

Chen, Xinjie et al. (2023) ‘Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients’, NeuroImage: Clinical, 37. Available at: https://doi.org/10.1016/j.nicl.2023.103349.

Daruwalla, Cyrus et al. (2023) ‘Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis’, Multiple Sclerosis Journal, 29, pp. 875–883. Available at: https://doi.org/10.1177/13524585231151951.

Disanto, Giulio et al. (2023) ‘Longitudinal serum neurofilament light kinetics in post-anoxic encephalopathy’, Annals of Clinical and Translational Neurology, 10, pp. 2407–2412. Available at: https://doi.org/10.1002/acn3.51903.

Harding-Forrester, Sam et al. (2023) ‘Disability accrual in primary and secondary progressive multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94, pp. 707–717. Available at: https://doi.org/10.1136/jnnp-2022-330726.

Kalincik, Tomas et al. (2023) ‘Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology, 80, pp. 702–713. Available at: https://doi.org/10.1001/jamaneurol.2023.1184.

Kiss, Máté G. et al. (2023) ‘Interleukin-3 coordinates glial-peripheral immune crosstalk to incite multiple sclerosis’, Immunity, 56, pp. 1502–1514.e8. Available at: https://doi.org/10.1016/j.immuni.2023.04.013.

Körtvelyessy, Peter et al. (2023) ‘Serum neurofilament light chain in COVID-19 and the influence of renal function’, European Journal of Medical Research, 28. Available at: https://doi.org/10.1186/s40001-023-01375-1.

Leone, Maurizio A. et al. (2023) ‘Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis’, Cell Stem Cell, 30, pp. 1597–1609.e8. Available at: https://doi.org/10.1016/j.stem.2023.11.001.

Leppert, David et al. (2023) ‘Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94, pp. 726–737. Available at: https://doi.org/10.1136/jnnp-2022-330796.

Nittas, Vasileios et al. (2023) ‘Digital health for chronic disease management: An exploratory method to investigating technology adoption potential’, PLoS ONE, 18. Available at: https://doi.org/10.1371/journal.pone.0284477.

Overeem, Lucas Hendrik et al. (2023) ‘Serum tau protein elevation in migraine: a cross-sectional case–control study’, Journal of Headache and Pain, 24. Available at: https://doi.org/10.1186/s10194-023-01663-5.

Roos, Izanne et al. (2023) ‘Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology, 80, pp. 789–797. Available at: https://doi.org/10.1001/jamaneurol.2023.1625.

Rosenkranz, Sina C. et al. (2023) ‘Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94, pp. 924–933. Available at: https://doi.org/10.1136/jnnp-2023-331183.

Saraste, Maija et al. (2023) ‘Association of serum neurofilament light with microglial activation in multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94, pp. 698–706. Available at: https://doi.org/10.1136/jnnp-2023-331051.

Sharmin, Sifat et al. (2023) ‘The risk of secondary progressive multiple sclerosis is geographically determined but modifiable’, Brain, 146, pp. 4633–4644. Available at: https://doi.org/10.1093/brain/awad218.

Spelman, Tim et al. (2023) ‘A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry’, Neurodegenerative Disease Management, 13, pp. 215–221. Available at: https://doi.org/10.2217/nmt-2023-0005.

Sy, Michael et al. (2023) ‘N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial’, Journal of Neuroinflammation, 20. Available at: https://doi.org/10.1186/s12974-023-02893-9.

Telser, Julia et al. (2023) ‘Concentrations of Serum Brain Injury Biomarkers Following SARS-CoV-2 Infection in Individuals with and without Long-COVID—Results from the Prospective Population-Based COVI-GAPP Study’, Diagnostics, 13. Available at: https://doi.org/10.3390/diagnostics13132167.

Theil, Diethilde et al. (2023) ‘Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity’, Toxicologic Pathology, 51, pp. 135–147. Available at: https://doi.org/10.1177/01926233231180179.

Tsagkas, Charidimos et al. (2023) ‘Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis’, Multiple Sclerosis Journal, 29, pp. 702–718. Available at: https://doi.org/10.1177/13524585221139152.

Uher, Tomas et al. (2023) ‘Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences’, Multiple Sclerosis Journal, 29, pp. 1437–1451. Available at: https://doi.org/10.1177/13524585231197076.

Wenger A.L. et al. (2023) ‘An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis’, Frontiers in Neuroscience, 17. Available at: https://doi.org/10.3389/fnins.2023.1007580.

Wilson, David et al. (2023) ‘Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: Toward a clinical blood test for neuronal injury’, Clinical Chemistry and Laboratory Medicine, null. Available at: https://doi.org/10.1515/cclm-2023-0518.

Zetterberg H et al. (2023) ‘The role of neurofilament light in genetic frontotemporal lobar degeneration.’, Brain communications, 5(1), p. fcac310. Available at: https://doi.org/10.1093/braincomms/fcac310.

Zhu, Chao et al. (2023) ‘Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation’, JAMA Neurology, 80, pp. 739–748. Available at: https://doi.org/10.1001/jamaneurol.2023.1542.

Ziaei, Amin et al. (2023) ‘High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases’, Multiple Sclerosis and Related Disorders, 74. Available at: https://doi.org/10.1016/j.msard.2023.104704.

Ahmad, S. et al. (2022) Genome-wide Association Study Meta-analysis of Neurofilament light (NfL) levels in blood reveals novel loci related to neurodegeneration. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2022.12.14.22283446.

Le N.D. et al. (2022) ‘The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis’, Scientific Reports, 12(1). Available at: https://doi.org/10.1038/s41598-022-17282-0.

Wai C.H. et al. (2022) ‘Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria’, Scientific Reports, 12(1). Available at: https://doi.org/10.1038/s41598-022-14291-x.

Yeo T. et al. (2022) ‘Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model’, Journal of Neuroinflammation, 19(1). Available at: https://doi.org/10.1186/s12974-022-02614-8.

Zhu C et al. (2022) ‘Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.’, Journal of neurology, neurosurgery, and psychiatry, 93(12), pp. 1330–1337. Available at: https://doi.org/10.1136/jnnp-2022-330104.

Leone, M. et al. (2022) Foetal Allogeneic Intracerebroventricular Neural Stem Cell Transplantation in People with Secondary Progressive Multiple Sclerosis: A phase I dose-escalation clinical trial. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2022.11.14.22282124.

Kessler C et al. (2022) ‘Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4.’, International journal of molecular sciences, 23(21). Available at: https://doi.org/10.3390/ijms232113466.

Camara-Lemarroy C. et al. (2022) ‘Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels’, Multiple Sclerosis Journal, 28(13), pp. 2081–2089. Available at: https://doi.org/10.1177/13524585221109761.

Lin TY et al. (2022) ‘Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder’, Multiple Sclerosis and Related Disorders, 67. Available at: https://doi.org/10.1016/j.msard.2022.104100.

Stanikić M et al. (2022) ‘Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry.’, Multiple sclerosis and related disorders, 67, p. 104084. Available at: https://doi.org/10.1016/j.msard.2022.104084.

Herrera-Rivero, M. et al. (2022) Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum. Research Square Platform LLC. Available at: https://doi.org/10.21203/rs.3.rs-422221/v1.

Leppert D et al. (2022) ‘Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.’, Neurology, 99(14), p. 631. Available at: https://doi.org/10.1212/wnl.0000000000201277.

Manfredi-Lozano M. et al. (2022) ‘GnRH replacement rescues cognition in Down syndrome’, Science, 377(6610). Available at: https://doi.org/10.1126/science.abq4515.

Abdelhak A. et al. (2022) ‘Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 93(9), pp. 972–977. Available at: https://doi.org/10.1136/jnnp-2022-329221.

Rahmanzadeh R et al. (2022) ‘A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis.’, Annals of neurology, 92(3), pp. 486–502. Available at: https://doi.org/10.1002/ana.26441.

Ruder J. et al. (2022) ‘Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis’, International Journal of Molecular Sciences, 23(18). Available at: https://doi.org/10.3390/ijms231810946.

Van Hijfte L. et al. (2022) ‘Lifestyle factors in multiple sclerosis disability progression and silent brain damage: A cross-sectional study’, Multiple Sclerosis and Related Disorders, 65. Available at: https://doi.org/10.1016/j.msard.2022.104016.

Tzartos J.S. et al. (2022) ‘Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders’, Biomolecules, 12(8). Available at: https://doi.org/10.3390/biom12081099.

Voskuhl R. et al. (2022) ‘Decreased neurofilament light chain levels in estriol-treated multiple sclerosis’, Annals of Clinical and Translational Neurology, 9(8), pp. 1316–1320. Available at: https://doi.org/10.1002/acn3.51622.

Wendebourg MJ, Kuhle J. and Hardmeier M (2022) ‘Case Report: A 72-Year-Old Woman With Progressive Motor Weakness, Dry Eyes and High Levels of Serum Neurofilament Light Chain’, Frontiers in Neurology, 13. Available at: https://doi.org/10.3389/fneur.2022.889894.

Buhmann C. et al. (2022) ‘Reply to: “Diabetes and Neuroaxonal Damage in Parkinson’s Disease”’, Movement Disorders, 37(7), pp. 1569–1570. Available at: https://doi.org/10.1002/mds.29064.

Zuo M et al. (2022) ‘Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation.’, JCI insight, 7(12). Available at: https://doi.org/10.1172/jci.insight.158144.

Rubsamen N. et al. (2022) ‘A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies’, Frontiers in Neurology, 13. Available at: https://doi.org/10.3389/fneur.2022.894119.

Uyar M. et al. (2022) ‘Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson’s Disease (MARK-PD Study)’, Movement Disorders, 37(6), pp. 1299–1304. Available at: https://doi.org/10.1002/mds.29009.

Leppert D et al. (2022) ‘Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.’, Neurology, 98(21), pp. e2120–e2131. Available at: https://doi.org/10.1212/wnl.0000000000200258.